The estimated Net Worth of Thomas Ryll is at least $4.21 millió dollars as of 24 February 2020. Thomas Ryll owns over 16,790 units of Immunogen stock worth over $2,362,494 and over the last 7 years he sold IMGN stock worth over $277,365. In addition, he makes $1,566,750 as Vice President és Technical Operations at Immunogen.
Thomas has made over 3 trades of the Immunogen stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 16,790 units of IMGN stock worth $83,782 on 24 February 2020.
The largest trade he's ever made was selling 16,790 units of Immunogen stock on 24 February 2020 worth over $83,782. On average, Thomas trades about 3,651 units every 67 days since 2018. As of 24 February 2020 he still owns at least 75,624 units of Immunogen stock.
You can see the complete history of Thomas Ryll stock trades at the bottom of the page.
Dr. Thomas Ryll Ph.D. serves as Vice President, Technical Operations of the Company. serves as Vice President, Technical Operations of the Company. He joined ImmunoGen in 2015, Prior to that he served as Vice President, Process and Analytical Development, from his date of hire to 2017. Prior to joining ImmunoGen, he spent almost nine years at Biogen Inc. (formerly known as Biogen Idec Inc.), a biopharmaceutical company, in roles of increasing responsibility in the area of cell line culture development, including Senior Director in Biogen’s technical development department. Dr. Ryll holds a PhD in biotechnology and biochemistry from the Technical University of Braunschweig, Germany, and completed his post-doctoral work at the Society for Biotechnology Research (now the Helmholtz Center for Infection Research) in Germany.
As the Vice President és Technical Operations of Immunogen, the total compensation of Thomas Ryll at Immunogen is $1,566,750. There are 2 executives at Immunogen getting paid more, with Mark Enyedy having the highest compensation of $3,917,560.
Thomas Ryll is 58, he's been the Vice President és Technical Operations of Immunogen since 2017. There are 8 older and 8 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... és Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: